S&D Co (260970) Q2 2025 earnings summary

Executive summary

• Specializes in functional food ingredients and health supplements, with a focus on natural and bio-based products for B2B markets.

• No subsidiaries or affiliates; operates as a standalone entity.

• Recognized as a mid-sized enterprise and maintains certifications such as ISO, HACCP, and HALAL.

• Recent investments in production capacity and R&D, including new plant construction and product development.

Financial highlights

• 2025 H1 revenue: ₩73.8 billion, down from ₩116.1 billion in 2024 H1.

• Operating income for 2025 H1: ₩11.4 billion, net income: ₩9.3 billion.

• Gross margin improved to 38.3% in 2025 H1 from 34.7% in 2024 H1.

• Basic EPS for 2025 H1: ₩3,222, up from ₩1,354 in 2024 H1.

• Cash and cash equivalents at 2025 H1: ₩15.4 billion.

Outlook and guidance

• No specific forward guidance provided; company is preparing for further diversification and potential entry into new business areas.

• Plans to leverage existing functional food ingredient expertise for expansion into finished product markets.